Optimizing therapy of seizures in patients with endocrine disorders

Neurology

Volumn 67, Issue 12, 2006, Pages

  Steinhoff, Bernhard J ^a,b  

^a Epilepsiezentrum Kork   (Germany)

^b Epilepsiezentrum Kork   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTITHYROID AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; PRIMIDONE; THYROXINE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

APPETITE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SUBSTITUTION; ENDOCRINE DISEASE; ENERGY BALANCE; GENETIC DISPOSITION; GLUCOSE METABOLISM; HORMONE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; HYPOTHYROIDISM; INSULIN BLOOD LEVEL; INSULIN METABOLISM; INSULIN RESISTANCE; LEPTIN METABOLISM; LIVER DISEASE; MONOTHERAPY; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SEIZURE; SIDE EFFECT; THIRST; THYROID DISEASE; THYROXINE BLOOD LEVEL; WATER RETENTION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 33845685682     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.67.12_suppl_4.s23     Document Type: Review

References (64)

1. Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004;63(suppl 4):S3-8.
2. Steinhoff BJ. Nebenwirkungen der Antiepileptika. In: Fröscher W, Hufnagel A, Vassella F, eds. Die Epilepsien. Grundlagen - Klinik - Behandlung. Stuttgart, New York: Schattauer 2004:564-602.
3. Dinesen H, Gram L, Anderson T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-69.
4. Ettinger, A, Moshe S, Shinnar S. Edema associated with long-term valproate therapy. Epilepsia 1990;32:211-213.
5. Steinhoff BJ, Hirsch E, Mutani R, Nakken KO. The ideal characteristics of an antiepileptic therapy: an overview of old and new AEDs. Acta Neurol Scand 2003;107:87-95.
6. Ciampani M, Verrotti A, Chiarelli F. Sex hormones in patients with epilepsy-hormonal changes in epileptic men and women taking antiepileptics. Horm Metab Res 1005;37:184-188.
7. Morris GL III, Vanderkolk C. Human sexuality, sex hormones, and epilepsy. Epilepsy Behav 2005;7(suppl 2):22-28.
8. Pack A. Effects of treatment of endocrine function in patients with epilepsy. Curr Treat Options Neurol 2005;7:273-280.
9. Fichsel H. Hormonelle Veränderungen unter Antikonvulsiva. In: Hallen O, Meyer-Wahl JG, Braun J, eds. Epilepsie 82. Wandsbek: Einhorn-Presse 1984:119-128.
10. Caksen H, Dulger H, Cesur Y, Atas B, Tunce O, Odabas D. Evaluation of thyroid and parathyroid functions in children receiving long-term carbamazepine therapy. Int J Neurosci 2003;113:1213-1217.
11. Caksen H, Dulger H, Cesur Y, Odabas D, Tuncer O, Atas B. No effect of long-term VPA therapy on thyroid and parathyroid functions in children. Int J Neurosci 2002;112:1371-1374.
12. Vainionpää LK, Mikkonen K, Rattyä J, et al. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia 2004;45:197-203.
13. Chin W, Schussler GC. Decreased serum free thyroxine concentration in patients treated with diphenylhydantoin. J Clin Endocrinol Metab 1968;28:181-186.
14. Larsen PR, Atkinson AJ Jr, Wellman HN, Goldsmith RE. The effect of diphenylhydantoin on thyroxine metabolism in man. J Clin Invest 1970;49:1266-1279.
15. Krause KH. Nebenwirkungen von Antiepileptika bei Langzeitmedikation. Eine klinisch-statistische Studie. Berlin, Heidelberg, New York, London, Paris, Tokyo: Springer, 1988.
16. Isojärvi JIT, Turkka J, Pakarinen AJ, Kotila M, Rattya J, Myllylä V. Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy. Epilepsia 2001;42:930-934.
17. Verrotti A, Basciani F, Morresi S, Morgese G, Chiarelli F. Thyroid hormones in epileptic children receiving carbamazepine and valproic acid. Pediatr Neurol 2001;25:43-46.
18. Eiris-Punal J, el Rio-Garma M, Del-Rio Garma MC, Lojo-Rocamonde S, Novo-Rodriguez I, Castro-Gago M. Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism. Epilepsia 1999;40:1761-1766.
19. Rootvelt K, Ganes T, Johannessen SI. Effect of carbamazepine, phenytoin and phenobarbitone on serum levels of thyroid hormones and thyreotropin in humans. Scand J Clin Lab Invest 1978;38:731-736.
20. Gharib H, Munoz JM. Endocrine manifestations of diphenylhydantoin therapy. Metabolism 1974;23:515-524.
21. Ericsson U-B, Bjerre I, Forsgren M, et al. Thyroglobulin and thyroid hormones in patients on long-term treatment with phenytoin, carbamazepine, and valproic acid. Epilepsia 1985;26:594-596.
22. Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 2000;14:301-319.
23. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61:246-255.
24. Ackermann S, Nolan LJ. Bodyweight gain induced by psychotropic drugs. CNS Drugs 1998;9:135-151.
25. DeToledo JC, Toledo C, DeCerce J, Ramsay RE. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997;19:394-396.
26. Hogan RE, Bertrand ME, Deaton RL, Sommerville KW. Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. Epilepsy Res 2000;41:23-28.
27. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saft 2001;24:969-978.
28. Bauer J. Gewichtszunahme und Endokrinopathie unter Valproinsä uretherapie. In: Krämer, G, Walden J, eds. Valproinsäure. Pharmakologie, klinischer Einsatz, Nebenwirkungen und Therapierichtlinien. 2. Springer, Berlin, Heidelberg, New York: Springer 2002;342-358.
29. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin 1008-011 International Study Group. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004;45:20-27.
30. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981;283:577-581.
31. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-177.
32. Morrell MJ, Isojärvi J, Taylor AE, et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res 2003;54:189-199.
33. Gidal BE, Sheth RD, Magnus L, Herbeuval AF. Levetiracetam does not alter body weight: analysis of randomised, controlled clinical trials. Epilepsy Res 2003;56:121-126.
34. Luef GJ, Lechleitner M, Bauer G, Trinka E, Hengster P. Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res 2003;55:53-58.
35. Perucca E, Garatt A, Hebdige S, Richens A. Water intoxication in epileptic patients receiving carbamazepine. J Neurol Neurosurg Psychiatry 1978;41:713-718.
36. Verrotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999;53:230-232.
37. Pylvanen V, Knip M, Pakarinen A, Kotila M, Turkka J, Isojärvi JI. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002;43:514-517.
38. Laub MC, Paetzke-Brunner I, Jaeger G. Serum carnitine during valproic acid therapy. Epilepsia 1986;27:559-562.
39. Verrotti A, Basciani F, De Simone M, Trotta D, Morgese G, Chiare F. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol 2002;17:265-268.
40. Luef G, Abraham I, Hoppichler F, et al. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 2002;51:1274-1278.
41. Stephen LJ, Kwan P, Shapiro D, Dominiczak M, Brodie MJ. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 2001;42:1002-1006.
42. Isojärvi JIT, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-451.
43. Rattya J, Vainionpaa L, Knip M, Lanning P, Isojärvi JI. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999;103:588-593.
44. Luef GJ, Waldmann M, Sturm W, et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 2004;55:729-732.
45. Murialdo G, Galimberti CA, Gianelli MV, et al. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998;21:52-58.
46. Bauer J, Jarre E, Klingmüller D, Elger CE. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000;41:163-167.
47. Bauer J, Penin H, Burr W. Nebenerscheinungen unter Valproinsä uretherapie im Erwachsenenalter. Nervenarzt 1988;59:26-31.
48. Bergen DC, Ristanovic RK, Waicosky K, Kanner A, Hoeppner TJ. Weight loss in patients taking felbamate. Clin Neuropharmacol 1995;18:23-27.
49. Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2001;41(suppl 1):S66-71.
50. Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial seizures. Epilepsia 1997;38:294-300.
51. Chengappa KN, Chalasani L, Brar JS, Parepally H, Houck P, Levin J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, non-randomized chart review. Clin Ther 2002;24:1576-1584.
52. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003;160:255-261.
53. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M. OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004;28:1399-1410.
54. Wilkes JJ, Nelson E, Osborne M, Demarest KT, Olefsky JM. Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol 2005;288:E617-624.
55. Gadde KM, Franciscy DM, Wagner HR II, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289:1820-1825.
56. McElroy SL, Kotwal R, Hudosn JI, Nelson EB, Keck PE. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. Clin Psychiatry 2004;65:50-56.
57. Ness-Abramof R, Apovian CM. Drug-induced weight gain. Timely Top Med Cardiovasc Dis 2005;28:E31.
58. Halpern A, Mancini MC. Diabesity: are weight loss medications effective? Treat Endocrinol 2005;4:65-74.
59. Penumakee S, Kissner PZ, Migdal SD. Gabapentin-induced hypoglycemia in a long-term peritoneal dialysis patient. Am J Kidney Dis 2003;42:E3-5.
60. Klein JP. Diphenylhydantoin intoxication associated with hyperglycemia. J Pediatr 1966;69:463-465.
61. Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH. Effect of diphenylhydantoin on insulin secretion in man. N Engl J Med 1972;286:339-342.
62. Cummings NP, Rosenbloom AL, Kohler WC, Wilder BJ. Plasma glucose and insulin responses to oral glucose with chronic diphenylhydantoin therapy. Pediatrics 1973;51:1091-1093.
63. Karp M, Lerman P, Doron M, Laron Z. Effect of diphenylhydantoin on insulin response in the oral glucose tolerance test in children and adolescents. Helv Padiat Acta 1973;28:617-620.
64. Perry-Keene DA, Larkins RG, Heyma P, Peter CT, Ross D, Sloman JG. The effect of long-term diphenylhydantoin therapy on glucose tolerance and insulin secretion: a controlled trial. Clin Endocrinol (Oxford) 1980;12:575-580.